Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment

  • Technology appraisal guidance
  • TA1063
  • Published: 

History

Documents created during the development process.

Expected publication

Final draft guidance: 1

Draft guidance

Declaration of interests

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6370